ISSN Approved Journal || eISSN: 2582-8185 || CODEN: IJSRO2 || Impact Factor 8.2 || Google Scholar and CrossRef Indexed
Fast Publication within 48 hours || Low Article Processing Charges || Peer Reviewed and Referred Journal || Free Certificate
A review of the research on the cardiovascular risk factors and treatment options for Type II diabetic patients
1 School of Nursing, Noida International University, Greater Noida (UP), India.
2 Government Institute of Medical Sciences, Greater Noida (UP), India.
3 Teerthanker Mahaveer College of Nursing, TMU Moradabad, India.
4 Department of Obstetrics and Gynecology Maheshwari Nursing and Paramedical Institute Aligarh, U.P. India.
5 Department of Medical-Surgical Nursing, Maheshwari Nursing and Paramedical Institute, Aligarh. U.P. India.
6 ESIC Hospital, Lucknow, India.
7 J J Hospital. J J Marg, Nagpada-Mumbai Central, Off Jijabhoy Road, Mumbai, Maharashtra, India.
Review
International Journal of Science and Research Archive, 2023, 09(01), 286–293.
Article DOI: 10.30574/ijsra.2023.9.1.0356
Publication history:
Received on 28 March 2023; revised on 16 May 2023; accepted on 19 May 2023
Abstract:
The rise in the prevalence of diabetes is attributed to changes in human behavior, environment, and lifestyle. The prolonged survival of diabetes patients has been made possible by better care, but this is accompanied by chronic long-term problems brought on by hyperglycemia. Diabetes-related conditions like ketoacidosis or hypoglycemia are fewer common causes of death for diabetics than cardiovascular disease (CVD). Cardiovascular disease is more common in diabetes patients by a factor of 2 to 6 compared to the general population. Additionally, diabetics with CVD have a worse prognosis for survival than those with CVD who don't have diabetes, and their quality of life also declines. As a result, diabetes has been compared to a non-diabetic patient who has a history of heart disease in terms of risk. Identifying patients with a high risk of developing CVD can help prevent or delay cardiovascular events. Chemists must closely monitor these issues to manage CVD prevention and related ones. Patients taking aspirin and clopidogrel for an extended period should be constantly monitored due to the possibility of resistance. Guidelines have been developed to monitor and manage aspirin and clopidogrel in CVD preventive therapy.
Keywords:
Blood pressure; cardiovascular disease; Dyslipidemia; Homocysteine Inflammation; Insulin resistance; Microalbuminuria; Obesity; Postprandial Hyperglycemia; Type 2 diabetes mellitus
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
